Type 2 diabetes mellitus, pandemic in 21st century

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 42-50

  Ginter, Emil ^a   Simko, Vlado ^b  

^a INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; BIGUANIDE DERIVATIVE; FATTY ACID; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

AFRICA SOUTH OF THE SAHARA; AGING; ARTICLE; ASIA; AUSTRIA; BODY FAT; BROWN ADIPOSE TISSUE; CHINA; DISEASE ASSOCIATION; DRUG TARGETING; EPIDEMIC; HUMAN; ICELAND; INDIA; INSULIN RESISTANCE; MIDDLE EAST; NERVE DEGENERATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NORWAY; OBESITY; PANDEMIC; PHYSICAL ACTIVITY; PREVALENCE; RISK FACTOR; SAUDI ARABIA; SOUTH AND CENTRAL AMERICA; SWITZERLAND; UNITED STATES; URBANIZATION; WEIGHT GAIN; HEALTH; PATHOPHYSIOLOGY; REVIEW; STATISTICS;

DIABETES MELLITUS, TYPE 2; HUMANS; OBESITY; PANDEMICS; PREVALENCE; WORLD HEALTH;

MLCS; MLOWN;

EID: 84874535427     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_6     Document Type: Article

References (26)

1. Diabetes Atlas, Internation al Diabetes Federation, USA, 2007.
2. Roglic G, Green A et al. Prevalence of diabetes. Estimates tor the year 2000 and projection for 2030. Diabetes Care 2004; 27:1047-1053.
3. WHO. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Geneva, Switzerland, 2009.
4. CDC. Centres for Disease Control and Prevention. Atlanta, USA, 2007.
5. James WPT, Jackson-Leach R, Mhurdu CN et al. Overweight and obesity. In: Ezzati M, Lopez AD, Rodgers A et al, eds. Comparative Quantification of Health Risks. WHO, Geneva, 2003.
6. Basdevant A, Ciangura C. Obesity, a disease. Bull Aead Natl Med 2010; 194(1): 13-20.
7. Hummasti S, Hotamisligil GS. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Cire Res 2010; 107(5):579-591.
8. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Amer 2008; 37(3):635-646.
9. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 2006; 6(3): 177-181.
10. Wilding JP. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med 2007; 24(9):934-945.
11. Ioannidis I. The road from obesity to type 2 diabetes. Angiology 2008; 59(2 Suppl):39S-43S.
12. Lele RD. Pro-insulin, C peptide, glucagon, adiponectin, TNF alpha, AMPK: neglected players in type 2 diabetes mellitus. J Assoc Physicians India 2010; 58:35-40.
13. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93(11 Suppl 1):S64-S73.
14. Keller U. From obesity to diabetes. Int J Vitam Nutr Res 2006; 76(4): 172-177.
15. Dardeno TA, Chou SH, Moon HS et al. Leptin in hum an physiology and therapeutics. Front Neuroendocrinol 2010; 31(3):377-393.
16. Viollet B, Lantier L, Devin-Leclerc J et al. Targeting the AMPK pathway for the treatment of type 2 diabetes. Front Biosci 2009; 14:3380-3400.
17. Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006; 116(7):1776-1783.
18. Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes 2008; 32 Suppl 4:S712.
19. Christian M, Parker MG. The engineering of brown fat. J Molec Cell Bioi 2010; 2(1):23-25.
20. Ginter E, Simko V. Adult obesity at the beginning of the 21st century: epidemiology, pathoph ysiology and health risk. Bratisl Lek Listy 2008; 109(5):224-230.
21. Cypess AM, Lehman S, Williams G et al. Identification and importance of brown adipose tissue in adult humans. New Eng J Med 2009; 360:1509-1517.
22. De la Monte SM, Longato L, Tong M et al. Insulin resistance and neurode gene ration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs 2009; 10(10):1049-1060.
23. Daniels SR, Jacobson MS, McCrindle BW et al. American Heart Association Childhood Obesity Research Summit: executive summary. Circulation 2009; 119(15):2114-2123.
24. Gordon-Larsen P, Boone-Heinon J, Sidney S et al. Active commuting and cardiovascular disease risk. The CARDIA study. Arch Intern Med 2009; 169:1216-1223.
25. Ferencik M, Hulin I. Obesity, fatty tissue and inflammation. Med Monitor 2008; 4:16.
26. Mudaliar S, Henry RR. Incretin therapies: Effects beyond glycemic control. Am J Med 2009; 122:S25-S36.